期刊文献+

帕利哌酮和奥氮平治疗精神分裂症急性期的对照研究 被引量:25

Comparative study for treatment with Paliperidone release tablets and Olanzapine in schizophrenia
下载PDF
导出
摘要 目的比较帕利哌酮和奥氮平治疗精神分裂症急性期的疗效及不良反应。方法选择本院2010年1月至2011年1月住院精神分裂症急性期患者66例,随机分为帕利哌酮组(n=32),予帕利哌酮初始剂量为6 mg/d,可在1~2周根据病情及耐受性,加至9 mg/d或下调至3 mg/d,如果下调到3 mg/d后耐受但疗效不佳,可以调回到6 mg/d,平均剂量为(6.25±2.75)mg/d。奥氮平组34例,予奥氮平初始剂量5 mg/d,1周内加至10 mg/d。比较两组疗效。结果帕利哌酮起效较快,但奥氮平对焦虑抑郁、缺乏活动及行为障碍等症状疗效较好。帕利哌酮使患者体质量增加轻微,对代谢影响较小。奥氮平使患者泌乳及月经紊乱发生率低于帕利哌酮。结论帕利哌酮与奥氮平治疗精神分裂症急性期均有效,且不良反应少,安全性高。 Objective To compare the efficacy and side effects of Paliperidone release tablets and Olanzapine in treating acute schizophrenia.Methods 68 patients with acute schizophrenia were randomly assigned to the group treated with Paliperidone release tablets(32 cases) or Olanzapine(34 cases).The initial dosage of paliperidone release tablets was 6 mg/d which could be adjusted 9 mg/d or 3 mg/d according to the situation of the patients and their tolerance.The average usage was(6.25±2.75)mg/d.To the olanzapine group,the initial dosage was 5 mg/d,and increased to 10 mg/d within one week.And then effects of the two groups were compared.Results Paliperidone release tablets got the efficacy rapidly.Olanzapine was better than Paliperidone release tablets in treating anxiety,depression,lacking of energy and behavior disorders.There were not serious adverse reactions in the duration of treatment.The advantage of Paliperidone release tablets wsd less weight gain.The advantage of Olanzapine was less lactation and menstrual disorder.Conclusion The treatment of Paliperidone release tablets and Olanzapine in acute schizophrenia is effective,with few side effects and safe..
出处 《重庆医学》 CAS CSCD 北大核心 2011年第27期2751-2753,共3页 Chongqing medicine
关键词 帕利哌酮 奥氮平 精神分裂症 paliperidone release tablets olanzapine schizophrenia
  • 相关文献

参考文献15

  • 1Marder SR,Meibach RC. Risperidone in the treatment of schizophrenia[J]. Am J Psychiatry,1994,151(5):825.
  • 2Meltzer HY. Pre-clinical pharmacology of atypical antip- sychotic drugs : a selective review[J]. Br J Psychiatry Sup- pl,1996(29) :23-31.
  • 3Tollefson GD, Birkett MA, Kisesles GM, et al. Double- blind comparison of olazapine versus clozapine in schizo- phrenic patients clinically eligible for treatment with cloz- apine[J]. Biological Psychiatry, 2001,49 ( 1 ) : 52-63.
  • 4Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic[J]. Drugs Today(Barc), 2007,43 (4) : 249-258.
  • 5Yang LP, Plasker GL. Paliperidone extended release[J]. CNS Drugs,2007,21(5) :417-425.
  • 6Pani Li,Marchese G. Expected clinical benefits of paliper- idone extended-release formulation when compared with risperidone immediate-release[J]. Expert Opin Drug De- liv, 2009,6(3) : 319-331.
  • 7Boom S, Talluri K,Janssens L, et ah Single-and multiple- dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release [J]. J Clin Pharmacol, 2009,49 ( 11 ) : 1318-1330.
  • 8Marder SR,Kramer M,Ford L, et al,Efficacy and safety of paliperdone extended-release tablets: results of a 6- week,randomized, placebo controlled study[J]. Biol Psy- chiat, 2007,62 (12) : 1363-1370.
  • 9Vermeir M, Naessens I, Remmerie B, et al. Absorption metabolism,and excretion of paliperidone, a new mono- aminergic antagonist, in humans [J]. Drug Metab Dispos, 2008,36(4) :769-779.
  • 10Kan J, Canas F, Kramer M, et al. Treatment of schizo- phrenia with paliperidone extended-release tablets: a 6- week placebo-controlled trial[J]. Schizophr Res, 2007,90 (1/3) :147-161.

同被引文献184

引证文献25

二级引证文献165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部